Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

123.76 -1.69 (-1.35%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

June 15, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

June 12, 2026

From Gilead Sciences, Inc.

Via Business Wire

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

June 11, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

June 08, 2026

From Gilead Sciences, Inc.

Via Business Wire

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

June 08, 2026

From Merck & Co., Inc.

Via Business Wire

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

June 05, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

June 04, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

June 02, 2026

From Gilead Sciences, Inc.

Via Business Wire

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

May 27, 2026

From Gilead Sciences, Inc.

Via Business Wire

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

May 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

May 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

May 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

May 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

May 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Prices $3 Billion of Senior Unsecured Notes

May 14, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

May 13, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Announces First Quarter Financial Results

May 07, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

May 01, 2026

From Gilead Sciences, Inc.

Via Business Wire

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

April 29, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

April 28, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

April 17, 2026

From Gilead Sciences, Inc.

Via Business Wire

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

April 14, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

April 07, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Extends Tender Offer to Acquire Arcellx

April 01, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

March 23, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

March 02, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

February 25, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Present at Upcoming Investor Conferences

February 23, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

From Arcellx, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.